In this episode of Meeting Mic, we bring you pearls and perspectives in breast cancer from ASCO Annual Meeting. In an interview, Jame Abraham, MD, discusses the DESTINY-Breast05 study, as well as clinical and demographic risk factors for interstitial lung disease and radiation pneumonitis.

Next, Shimoli Barot, MD, discusses results from the phase 3 lidERA BC clinical trial of premenopausal vs. postmenopausal women with breast cancer.

Sara A. Hurvitz, MD, FACP, provides an overview of the ASCENT-03 study of a subset of women with triple-negative breast cancer.

And, Sherry Shen, MD, talks about a presentation on mutational signatures and related outcomes in metastatic invasive lobular carcinoma.

Read the full coverage here:

VIDEO: Clinicians 'should continue to pay attention' to T-DXd side effects in breast cancer

Untch M, et al. Abstract 516. Presented at: ASCO Annual Meeting; May 29-June 2, 2016; Chicago.

VIDEO: Giredestrant improves breast cancer survival, regardless of menopause status

Healio Interviews

VIDEO: Sacituzumab govitecan delays subsequent therapy in breast cancer subset

Hurvitz SA. Abstract 1001. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

VIDEO: Survival in metastatic invasive lobular carcinoma differs by mutational signature

Shen S, et al. Abstract 1141. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

'Reassuring': Omitting full axillary dissection does not worsen survival in breast cancer

De Boniface J, et al. Abstract LBA503. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

Abraham reports research funding from AstraZeneca/Daiichi Sankyo and Pfizer. Barot and Shen report no relevant financial disclosures. Hurvitz reports research funding from AstraZeneca/Daiichi Sankyo, Novartis and Stemline Therapeutics; and advisory or consulting roles with Akari Therapeutics, ALX Oncology, Bayer, BeOne Medicines, Blueprint Medicines, Boundless Bio, BriaCell, BridgeBio Pharma, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly Oncology, Ellipses Pharma, EMBioSys, Gilead Sciences, Jazz Pharmaceuticals, Luminate Medical, Mersana Therapeutics, Myricx Bio, Prelude Therapeutics and Roche.